Pathophysiology of the ovarian hyperstimulation syndrome
- PMID: 3927208
Pathophysiology of the ovarian hyperstimulation syndrome
Abstract
Ovarian hyperstimulation syndrome occurred after induction of ovulation with menotropins (follicle-stimulating hormone and luteinizing hormone) and implantation of an intrauterine pregnancy. Serial determinations of aldosterone, deoxycorticosterone, 17 beta-estradiol, progesterone, human chorionic gonadotropin, urinary and plasma electrolytes, and fluid balance were obtained. Plasma renin activity, aldosterone, deoxycorticosterone, and antidiuretic hormone rose markedly. Hydration for four days improved urinary output but also accelerated sodium and fluid retention. Subsequent restriction of salt and water stabilized the patient. Spontaneous abortion was followed by prompt diuresis without a change in therapy. Regression analysis of the authors' data, the clinical observations, and other data in the literature suggest that the ovarian hyperstimulation syndrome is produced by excessive secretion of an unknown hormone that regulates peritoneal fluid during the normal menstrual cycle, and that elevations of plasma renin, aldosterone, and antidiuretic hormone are secondary.
Similar articles
-
Ovarian hyperstimulation syndrome following ovulation induction with human menopausal gonadotropin.Int J Fertil. 1984;29(2):113-7. Int J Fertil. 1984. PMID: 6148315
-
Comparison between human urinary follicle-stimulating hormone and human menopausal gonadotropin treatment in polycystic ovary.Obstet Gynecol. 1984 Jan;63(1):6-11. Obstet Gynecol. 1984. PMID: 6419189
-
Ovulation induction with a starting dose of 50 IU of recombinant follicle stimulating hormone in WHO group II anovulatory women: the IO-50 study, a prospective, observational, multicentre, open trial.BJOG. 2003 Dec;110(12):1072-7. BJOG. 2003. PMID: 14664878 Clinical Trial.
-
Induction of ovulation in the patient with polycystic ovarian disease.Endocrinol Metab Clin North Am. 1988 Dec;17(4):733-49. Endocrinol Metab Clin North Am. 1988. PMID: 3143566 Review.
-
[The hyperstimulation syndrome].Gynakologe. 1991 Jun;24(3):130-5. Gynakologe. 1991. PMID: 1909990 Review. German. No abstract available.
Cited by
-
Treatment of Ovarian Hyperstimulation Syndrome in a Mouse Model by Cannabidiol, an Angiogenesis Pathway Inhibitor.Biomed Res Int. 2022 Dec 21;2022:1111777. doi: 10.1155/2022/1111777. eCollection 2022. Biomed Res Int. 2022. PMID: 36588534 Free PMC article.
-
Use of buserelin and low-dose human menopausal gonadotropin for in vitro fertilization in women at risk of ovarian hyperstimulation syndrome.J Assist Reprod Genet. 1995 Apr;12(4):252-7. doi: 10.1007/BF02212927. J Assist Reprod Genet. 1995. PMID: 7580021 Clinical Trial.
-
Ovarian hyperstimulation.BMJ. 1991 Feb 23;302(6774):474. doi: 10.1136/bmj.302.6774.474. BMJ. 1991. PMID: 1824018 Free PMC article. No abstract available.
-
Ovarian hyperstimulation syndrome: a review of pathophysiology.J Assist Reprod Genet. 1992 Oct;9(5):429-38. doi: 10.1007/BF01204048. J Assist Reprod Genet. 1992. PMID: 1482837 Review. No abstract available.
-
Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries.Am J Pathol. 2003 Jun;162(6):1881-93. doi: 10.1016/S0002-9440(10)64322-2. Am J Pathol. 2003. PMID: 12759245 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources